Skip to main content

Bruker Value Stock - Dividend - Research Selection

Bruker

ISIN: US1167941087 , WKN: 813534

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Allspring Common Stock Fund Q4 2025 Performance Review

2026-01-28

Artisan Small Cap Fund Q4 2025 Portfolio Activity

2026-01-23

Bruker Corporation (BRKR): A Bull Case Theory

2026-01-19
We came across a bullish thesis on Bruker Corporation on r/valueinvesting by TheDynamicMolecule. In this article, we will summarize the bulls’ thesis on BRKR. Bruker Corporation’s share was trading at $48.39 as of January 16th. BRKR’s trailing and forward P/E were 66.98 and 21.83 respectively according to Yahoo Finance. Bruker Corporation has established itself as a leading player in […]

Assessing Bruker (BRKR) Valuation After Recent Share Price Rebound And Conflicting Fair Value Signals

2026-01-17
Why Bruker (BRKR) is on investors’ radar today Bruker (BRKR) has drawn attention after a period of mixed share performance, with a 1 day return of about a 2% decline, alongside a roughly 9% gain over the past month and about 31% over the past 3 months. See our latest analysis for Bruker. Recent trading has been choppy. The 7 day share price return shows an 11.2% decline, compared with a 30 day share price return of 9% and a 90 day share price return of 30.9%. At the same time, the 1 year...

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

2026-01-16
TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported sev

1 Healthcare Stock Worth Investigating and 2 That Underwhelm

2026-01-16
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 21.1% over the past six months, topping the S&P 500 by 10.6 percentage points.

Why Bruker (BRKR) Shares Are Plunging Today

2026-01-13
Shares of scientific instrument company Bruker (NASDAQ:BRKR). fell 6.4% in the morning session after the company provided a weak organic revenue growth forecast for 2026 following a challenging 2025.

Bruker Teases 2026 Margin Surge, $120M Cost Cuts and Double-Digit EPS Growth After Rough 2025

2026-01-13
Bruker (NASDAQ:BRKR) executives used a conference presentation and Q&A session to outline what they described as an “incremental evolutionary” update for 2026, following a challenging 2025. Management emphasized a shift toward profitability and recurring revenue while continuing to invest in pos

Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-13
2026-01-13. The following slide deck was published by Bruker Corporation in conjunction with this event.

Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12
Bruker Corporation (BRKR) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:00 PM ESTCompany ParticipantsFrank Laukien - Chairman, CEO &...